Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 5/20 | 0.61 |
| ▸ | SRC | P12931 | 11/20 | 0.56 |
| ▸ | EGFR | P00533 | 10/20 | 0.56 |
| ▸ | ABL1 | P00519 | 9/20 | 0.56 |
| ▸ | ABL2 | P42684 | 9/20 | 0.56 |
| ▸ | LCK | P06239 | 5/20 | 0.53 |
| ▸ | KDR | P35968 | 5/20 | 0.53 |
| ▸ | LYN | P07948 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | RGS12 | O14924 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | GMNN | O75496 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074422 | 0.88 | SRC (0.67) | TEKSRCEGFRABL1ABL2 | |
| SCHEMBL12934129 | 0.87 | TEK (0.65) | TEKSRCEGFRABL1ABL2 | |
| SCHEMBL7006736 | 0.87 | TEK (0.65) | TEKSRCEGFRABL1ABL2 | |
| SCHEMBL2074647 | 0.87 | TEK (0.65) | TEKSRCEGFRABL1ABL2 | |
| SCHEMBL2075286 | 0.85 | TEK (0.81) | TEKSRCEGFRABL1ABL2 | |
| SCHEMBL12934130 | 0.85 | TEK (0.65) | TEKSRCEGFRABL1ABL2 | |
| SCHEMBL12934131 | 0.85 | TEK (0.63) | TEKSRCEGFRABL1ABL2 | |
| SCHEMBL2075322 | 0.85 | EGFR (0.52) | TEKSRCEGFRABL1ABL2 | |
| SCHEMBL12934134 | 0.85 | TEK (0.60) | TEKSRCEGFRABL1ABL2 | |
| SCHEMBL12934136 | 0.85 | TEK (0.62) | TEKSRCEGFRABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1114052-B1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2005-11-16 | — | — | EP | claimed |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-10-02 | — | — | US | claimed |
| US-7863444-B2 | 4-aminopyrrolopyrimidines as kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1114052-B1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2005-11-16 | — | — | EP | disclosed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | TEK 1465/4885SRC 46/4885EGFR 818/4885 |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | LCK, PPP5C, DUSP1 | TEK 199/4885SRC 89/4885EGFR 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.